-
1
-
-
0037097594
-
The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor
-
Chambers C.A., Kang J., Wu Y., Held W., Raulet D.H., Allison J.P. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood 2002, 99:4509-4516.
-
(2002)
Blood
, vol.99
, pp. 4509-4516
-
-
Chambers, C.A.1
Kang, J.2
Wu, Y.3
Held, W.4
Raulet, D.H.5
Allison, J.P.6
-
2
-
-
17644401665
-
MUC1 mucin-mediated regulation of human T cells
-
Agrawal B., Longenecker B.M. MUC1 mucin-mediated regulation of human T cells. Int. Immunol. 2005, 17:391-399.
-
(2005)
Int. Immunol.
, vol.17
, pp. 391-399
-
-
Agrawal, B.1
Longenecker, B.M.2
-
4
-
-
0028148592
-
Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules
-
Zrihan-Licht S., Baruch A., Elroy-Stein O., Keydar I., Wreschner D.H. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 1994, 356:130-136.
-
(1994)
FEBS Lett.
, vol.356
, pp. 130-136
-
-
Zrihan-Licht, S.1
Baruch, A.2
Elroy-Stein, O.3
Keydar, I.4
Wreschner, D.H.5
-
6
-
-
0034254301
-
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression
-
Carreno B.M., Bennett F., Chau T.A., Ling V., Luxenberg D., Jussif J., Baroja M.L., Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 2000, 165:1352-1356.
-
(2000)
J. Immunol.
, vol.165
, pp. 1352-1356
-
-
Carreno, B.M.1
Bennett, F.2
Chau, T.A.3
Ling, V.4
Luxenberg, D.5
Jussif, J.6
Baroja, M.L.7
Madrenas, J.8
-
7
-
-
0031914321
-
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
-
Agrawal B., Krantz M.J., Reddish M.A., Longenecker B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 1998, 4:43-49.
-
(1998)
Nat. Med.
, vol.4
, pp. 43-49
-
-
Agrawal, B.1
Krantz, M.J.2
Reddish, M.A.3
Longenecker, B.M.4
-
8
-
-
0037385330
-
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
-
Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
-
(2003)
Nat. Immunol.
, vol.4
, pp. 330-336
-
-
Fontenot, J.D.1
Gavin, M.A.2
Rudensky, A.Y.3
-
9
-
-
33847414082
-
Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood
-
Ahn J.S., Krishnadas D.K., Agrawal B. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood. Int. Immunol. 2007, 19:227-237.
-
(2007)
Int. Immunol.
, vol.19
, pp. 227-237
-
-
Ahn, J.S.1
Krishnadas, D.K.2
Agrawal, B.3
-
10
-
-
0032531005
-
Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation
-
Agrawal B., Krantz M.J., Parker J., Longenecker B.M. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 1998, 58:4079-4081.
-
(1998)
Cancer Res.
, vol.58
, pp. 4079-4081
-
-
Agrawal, B.1
Krantz, M.J.2
Parker, J.3
Longenecker, B.M.4
-
11
-
-
0033764673
-
Advances in interleukin 2 receptor targeted treatment
-
Morris J.C., Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. 2000, 59(Suppl 1):i109-114.
-
(2000)
Ann. Rheum. Dis.
, vol.59
, Issue.SUPPL. 1
-
-
Morris, J.C.1
Waldmann, T.A.2
-
12
-
-
79955629731
-
Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro
-
Huang J., Wang Q.J., Yang S., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J. Immunother. 2011, 34:327-335.
-
(2011)
J. Immunother.
, vol.34
, pp. 327-335
-
-
Huang, J.1
Wang, Q.J.2
Yang, S.3
Li, Y.F.4
El-Gamil, M.5
Rosenberg, S.A.6
Robbins, P.F.7
-
13
-
-
0038106670
-
Induction of CD4(+) T cell apoptosis as a consequence of impaired cytoskeletal rearrangement in UVB-irradiated dendritic cells
-
Termeer C.C., Wachter T., Averbeck M., Hara H., Tesmann J.P., Simon J.C., Denfeld R.W. Induction of CD4(+) T cell apoptosis as a consequence of impaired cytoskeletal rearrangement in UVB-irradiated dendritic cells. J. Immunol. 2003, 171:776-782.
-
(2003)
J. Immunol.
, vol.171
, pp. 776-782
-
-
Termeer, C.C.1
Wachter, T.2
Averbeck, M.3
Hara, H.4
Tesmann, J.P.5
Simon, J.C.6
Denfeld, R.W.7
-
14
-
-
33845698625
-
The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells
-
Yi H., Zhen Y., Jiang L., Zheng J., Zhao Y. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell. Mol. Immunol. 2006, 3:189-195.
-
(2006)
Cell. Mol. Immunol.
, vol.3
, pp. 189-195
-
-
Yi, H.1
Zhen, Y.2
Jiang, L.3
Zheng, J.4
Zhao, Y.5
-
16
-
-
0344153890
-
CD4(+)/CD25(+) regulatory cells inhibit activation of tumor-primed CD4(+) T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination
-
Lasarte J.J., Casares N., Arribillaga L., Sarobe P., Dotor J., de Cerio A.L.D., Melero I., Prieto J., Borras-Cuesta F. CD4(+)/CD25(+) regulatory cells inhibit activation of tumor-primed CD4(+) T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 2003, 171:5931-5939.
-
(2003)
J. Immunol.
, vol.171
, pp. 5931-5939
-
-
Lasarte, J.J.1
Casares, N.2
Arribillaga, L.3
Sarobe, P.4
Dotor, J.5
de Cerio, A.L.D.6
Melero, I.7
Prieto, J.8
Borras-Cuesta, F.9
-
17
-
-
34547774699
-
TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets
-
Pyzik M., Piccirillo C.A. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J. Leukoc. Biol. 2007, 82:335-346.
-
(2007)
J. Leukoc. Biol.
, vol.82
, pp. 335-346
-
-
Pyzik, M.1
Piccirillo, C.A.2
|